Trials / Terminated
TerminatedNCT01590342
Diclofenac for Submassive PE
Efficacy of Diclofenac for Patients With Acute Submassive Pulmonary Embolism: a Randomized Clinical Trial
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Ministry of Health, Spain · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to demonstrate the clinical benefits of diclofenac (added to standard anticoagulant therapy) over placebo in normotensive patients with acute symptomatic pulmonary embolism and right ventricular dysfunction. The secondary objective is to assess the safety after administration of diclofenac in normotensive patients with acute symptomatic pulmonary embolism and right ventricular dysfunction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Diclofenac | Diclofenac 75 mg, two doses |
| DRUG | Placebo | Placebo, two doses |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2017-01-01
- Completion
- 2017-06-01
- First posted
- 2012-05-02
- Last updated
- 2017-09-06
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT01590342. Inclusion in this directory is not an endorsement.